[D-p-Cl-Phe6,Leu17]-VIP
| Code | Size | Price |
|---|
| TAR-TP2103-1mg | 1mg | £311.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors.
CAS:
102805-45-8
Formula:
C148H239ClN44O42
Molecular Weight:
3342.24
Purity:
0.98
SMILES:
0
References
Pandol et al (1986) Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6,Leu17]VIP. Am.J.Physiol. 250 G553 PMID:
Xie et al (2007) Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol.Pharmacol. 72 73 PMID:
Pozo et al (1997) Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. Eur.J.Pharmacol. 321 379 PMID: